REGENXBIO Inc.

NasdaqGS:RGNX Voorraadrapport

Marktkapitalisatie: US$432.9m

REGENXBIO Toekomstige groei

Future criteriumcontroles 2/6

De verwachting is dat REGENXBIO de winst en omzet met respectievelijk 28.6% en 32.6% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 40.3% per jaar.

Belangrijke informatie

28.6%

Groei van de winst

40.3%

Groei van de winst per aandeel

Biotechs winstgroei27.5%
Inkomstengroei32.6%
Toekomstig rendement op eigen vermogenn/a
Dekking van analisten

Good

Laatst bijgewerkt28 Oct 2024

Recente toekomstige groei-updates

REGENXBIO Inc. (NASDAQ:RGNX) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Aug 04
REGENXBIO Inc. (NASDAQ:RGNX) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

REGENXBIO Inc. (NASDAQ:RGNX) Analysts Are Cutting Their Estimates: Here's What You Need To Know

May 11
REGENXBIO Inc. (NASDAQ:RGNX) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Recent updates

REGENXBIO: With Additional MPS II Data, Program Advancement Remains On Track

Oct 31

Does REGENXBIO (NASDAQ:RGNX) Have A Healthy Balance Sheet?

Sep 12
Does REGENXBIO (NASDAQ:RGNX) Have A Healthy Balance Sheet?

Regenxbio: RGX-121 Could Achieve A First For Rare Neurodegenerative Disorder

Aug 06

REGENXBIO Inc. (NASDAQ:RGNX) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Aug 04
REGENXBIO Inc. (NASDAQ:RGNX) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Revenues Working Against REGENXBIO Inc.'s (NASDAQ:RGNX) Share Price

Jul 26
Revenues Working Against REGENXBIO Inc.'s (NASDAQ:RGNX) Share Price

Regenxbio: Transforming Gene Therapy With Innovative AAV Treatments, Strong Buy

Jun 11

REGENXBIO Inc. (NASDAQ:RGNX) Analysts Are Cutting Their Estimates: Here's What You Need To Know

May 11
REGENXBIO Inc. (NASDAQ:RGNX) Analysts Are Cutting Their Estimates: Here's What You Need To Know

REGENXBIO Inc. (NASDAQ:RGNX) Not Doing Enough For Some Investors As Its Shares Slump 26%

Apr 25
REGENXBIO Inc. (NASDAQ:RGNX) Not Doing Enough For Some Investors As Its Shares Slump 26%

Regenxbio: DMD Program Lends Additional Credibility To NAV Technology Platform

Mar 11

Analysts Just Slashed Their REGENXBIO Inc. (NASDAQ:RGNX) EPS Numbers

Mar 07
Analysts Just Slashed Their REGENXBIO Inc. (NASDAQ:RGNX) EPS Numbers

Improved Revenues Required Before REGENXBIO Inc. (NASDAQ:RGNX) Stock's 75% Jump Looks Justified

Mar 05
Improved Revenues Required Before REGENXBIO Inc. (NASDAQ:RGNX) Stock's 75% Jump Looks Justified

Earnings Update: REGENXBIO Inc. (NASDAQ:RGNX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Mar 02
Earnings Update: REGENXBIO Inc. (NASDAQ:RGNX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Regenxbio: Robust Data, Decent Cash, Never Ending Trials, Buying At Dips

Jan 19

There's No Escaping REGENXBIO Inc.'s (NASDAQ:RGNX) Muted Revenues

Dec 21
There's No Escaping REGENXBIO Inc.'s (NASDAQ:RGNX) Muted Revenues

We Think REGENXBIO (NASDAQ:RGNX) Needs To Drive Business Growth Carefully

Nov 09
We Think REGENXBIO (NASDAQ:RGNX) Needs To Drive Business Growth Carefully

Will REGENXBIO (NASDAQ:RGNX) Spend Its Cash Wisely?

Aug 08
Will REGENXBIO (NASDAQ:RGNX) Spend Its Cash Wisely?

REGENXBIO Inc. (NASDAQ:RGNX) Analysts Just Trimmed Their Revenue Forecasts By 12%

May 11
REGENXBIO Inc. (NASDAQ:RGNX) Analysts Just Trimmed Their Revenue Forecasts By 12%

Here's Why We're Watching REGENXBIO's (NASDAQ:RGNX) Cash Burn Situation

May 08
Here's Why We're Watching REGENXBIO's (NASDAQ:RGNX) Cash Burn Situation

Analysts Are More Bearish On REGENXBIO Inc. (NASDAQ:RGNX) Than They Used To Be

Mar 05
Analysts Are More Bearish On REGENXBIO Inc. (NASDAQ:RGNX) Than They Used To Be

Winst- en omzetgroeiprognoses

NasdaqGS:RGNX - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/2026214-154-144N/A7
12/31/2025293-57156N/A11
12/31/2024109-227-173N/A11
6/30/202489-241-195-191N/A
3/31/202487-260-199-193N/A
12/31/202390-263-228-218N/A
9/30/202399-261-231-217N/A
6/30/202397-274-236-218N/A
3/31/2023110-270-257-232N/A
12/31/2022113-280-238-207N/A
9/30/202248074134173N/A
6/30/202248491128181N/A
3/31/2022474101143207N/A
12/31/2021470128135219N/A
9/30/202193-212-166-83N/A
6/30/2021161-145-147-77N/A
3/31/2021156-121-116-63N/A
12/31/2020155-111-81-54N/A
9/30/2020145-91-134-119N/A
6/30/202061-135-123-112N/A
3/31/202052-103-128-114N/A
12/31/201935-95-119-108N/A
9/30/201964-64-102-86N/A
6/30/201955-49-93-77N/A
3/31/201987-37417N/A
12/31/201821910091105N/A
9/30/2018180808495N/A
6/30/2018176789097N/A
3/31/201814253N/A18N/A
12/31/201710-73N/A-58N/A
9/30/201710-77N/A-65N/A
6/30/20179-74N/A-59N/A
3/31/20175-74N/A-58N/A
12/31/20165-63N/A-49N/A
9/30/20167-49N/A-33N/A
6/30/20168-38N/A-29N/A
3/31/20167-32N/A-29N/A
12/31/20158-24N/A-23N/A
9/30/20154-21N/A-18N/A
6/30/20154-16N/A-13N/A
3/31/20154-8N/A-5N/A
12/31/20146-5N/A-2N/A
12/31/20136-6N/A-3N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat RGNX de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat RGNX de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat RGNX de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van RGNX ( 32.6% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.8% per jaar).

Hoge groei-inkomsten: De omzet van RGNX ( 32.6% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van RGNX naar verwachting over 3 jaar hoog zal zijn

Ontdek groeibedrijven

7D

1Y

7D

1Y

7D

1Y